Difference between revisions of "Acute myeloid leukemia trial demographics"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "|NR" to "|Not reported") |
||
| Line 11: | Line 11: | ||
|55 (NR) | |55 (NR) | ||
|57/43 | |57/43 | ||
| − | | | + | |Not reported |
|ECOG 0-1: 86% | |ECOG 0-1: 86% | ||
|- | |- | ||
| Line 18: | Line 18: | ||
|56 (NR) | |56 (NR) | ||
|56/44 | |56/44 | ||
| − | | | + | |Not reported |
|ECOG 0-1: 87% | |ECOG 0-1: 87% | ||
|- | |- | ||
| Line 25: | Line 25: | ||
|47 (17-60) | |47 (17-60) | ||
|52/48 | |52/48 | ||
| − | | | + | |Not reported |
| − | | | + | |Not reported |
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480917/ ECOG E1900] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480917/ ECOG E1900] | ||
| Line 32: | Line 32: | ||
|48 (18-60) | |48 (18-60) | ||
|50/50 | |50/50 | ||
| − | | | + | |Not reported |
| − | | | + | |Not reported |
|- | |- | ||
|[https://doi.org/10.1056/NEJMoa0901409 HOVON 43 AML/SAKK 30/01] | |[https://doi.org/10.1056/NEJMoa0901409 HOVON 43 AML/SAKK 30/01] | ||
| Line 39: | Line 39: | ||
|67 (60-79) | |67 (60-79) | ||
|57/43 | |57/43 | ||
| − | | | + | |Not reported |
|ECOG 0-1: 88% | |ECOG 0-1: 88% | ||
|- | |- | ||
| Line 46: | Line 46: | ||
|67 (60-83) | |67 (60-83) | ||
|53/47 | |53/47 | ||
| − | | | + | |Not reported |
|ECOG 0-1: 88% | |ECOG 0-1: 88% | ||
|- | |- | ||
| Line 53: | Line 53: | ||
|43 (15-60)<sup>a</sup> | |43 (15-60)<sup>a</sup> | ||
|48/52 | |48/52 | ||
| − | | | + | |Not reported |
|KPS 90-100%: 80% | |KPS 90-100%: 80% | ||
|- | |- | ||
| Line 60: | Line 60: | ||
|43 (15-60)<sup>a</sup> | |43 (15-60)<sup>a</sup> | ||
|60/40 | |60/40 | ||
| − | | | + | |Not reported |
|KPS 90-100%: 82.5% | |KPS 90-100%: 82.5% | ||
|- | |- | ||
Latest revision as of 10:55, 6 July 2024
| Study | Arm | Age, median (range) | Sex (%M/%F) | Race | Performance Status |
|---|---|---|---|---|---|
| Wiernik et al. 1992 | 7+3d (standard-dose) | 55 (NR) | 57/43 | Not reported | ECOG 0-1: 86% |
| Wiernik et al. 1992 | 7+3i | 56 (NR) | 56/44 | Not reported | ECOG 0-1: 87% |
| ECOG E1900 | 7+3d (standard-dose) | 47 (17-60) | 52/48 | Not reported | Not reported |
| ECOG E1900 | 7+3d (high-dose) | 48 (18-60) | 50/50 | Not reported | Not reported |
| HOVON 43 AML/SAKK 30/01 | 7+3d (standard-dose) | 67 (60-79) | 57/43 | Not reported | ECOG 0-1: 88% |
| HOVON 43 AML/SAKK 30/01 | 7+3d (high-dose) | 67 (60-83) | 53/47 | Not reported | ECOG 0-1: 88% |
| ADcomparison | 7+3d (standard-dose) | 43 (15-60)a | 48/52 | Not reported | KPS 90-100%: 80% |
| ADcomparison | 7+3d (high-dose) | 43 (15-60)a | 60/40 | Not reported | KPS 90-100%: 82.5% |
aAge is not reported separately by arm.
This work is supported in part by NCI U24 CA265879.